Drug intelligence / Profile preview

Keziderm-L

Development stage: Unknown
Lead developer: Kaiser Drugs
Modality: Small Molecules
Administration: Topical

Overview

Keziderm-L is a topical antifungal cream containing luliconazole (1% w/w) and benzyl alcohol (1% w/w). Developed and distributed by Kaiser Drugs Private Limited, it is used for the treatment of various dermatological fungal infections of the skin. Luliconazole, the primary active ingredient, is an imidazole antifungal that works by inhibiting the enzyme lanosterol 14-alpha-demethylase, thereby disrupting the synthesis of ergosterol, a critical component of fungal cell membranes. This formulation is specifically designed for topical application to affected skin areas.

Brand names: Keziderm-L

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on Keziderm-L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keziderm-L.

Explore the full profile